Taufik Momin

Taufik Momin

Auto-generated profile, based on publicly available information

Taufik Momin

Zydus Lifesciences Ltd. Ahmedabad India

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 January 2023 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Closed access
MSMohammad Shadab Siddiqui
Mohammad Shadab Siddiqui
DPDeven Parmar
Deven Parmar
FSFarheen Sheikh
Farheen Sheikh
SSShiv Kumar Sarin
Shiv Kumar Sarin
LCLaura Cisneros
Laura Cisneros
ASArun J. Sanyal
Arun J. Sanyal

2 October 2024 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
RVRaj Vuppalanchi
Raj Vuppalanchi
MCMary M. Cruz
Mary M. Cruz
TMTaufik Momin
Taufik Momin
FSFarheen Shaikh
Farheen Shaikh
KSKimberly Swint
Kimberly Swint
DPDeven Parmar
Deven Parmar
Saroglitazar magnesium, a dual PPAR α/γ agonist, currently in Phase III for treating primary biliary cholangitis (PBC), was evaluated for its pharmacokinetic (PK) profile, safety, and pharmacodynamics in participants with cholestatic liver disease (CLD) across different levels of hepatic impairment (HI) and participants with severe renal impairment (RI). Three PK studies comparing saroglitazar with healthy controls were conducted: Study 1 involved daily oral doses of 1 or 2 mg for 4 weeks in 12 PBC cirrhosis participants with mild or moderate HI; Study 2 assessed single‐dose PK (2 or 4 mg) in eight non‐cirrhotic CLD participants; Study 3 evaluated single‐dose PK (2 mg) in eight participants with severe RI. On day 1, saroglitazar exposure increased by 14.6–42% in mild HI vs. normal, but by day 28, levels were similar, indicating no accumulation. In moderate HI, exposure was significantly increased by 50.4–85% on days 1 and 28, with 34–46% lower clearance despite a similar half‐life. The moderate HI group had a 59% higher exposure than the non‐cirrhotic group. Saroglitazar (1 and 2 mg) reduced alkaline phosphatase (ALP) levels by 17–40% after 4 weeks in participants with abnormal baseline ALP. Single‐dose PK in non‐cirrhotic CLD (2 and 4 mg) and severe RI (2 mg) was comparable to matched controls without significant safety issues. Overall, saroglitazar (1 and 2 mg) was safe and well‐tolerated in cholestatic cirrhosis with mild HI and participants with severe RI without major PK changes. Moderate HI increased exposure and decreased clearance without any safety concerns.